Cryolife (NYSE: CRY) and Steris (NYSE:STE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Risk & Volatility

Cryolife has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Steris has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.


Steris pays an annual dividend of $1.24 per share and has a dividend yield of 1.4%. Cryolife does not pay a dividend. Steris pays out 43.7% of its earnings in the form of a dividend. Cryolife has increased its dividend for 8 consecutive years.

Valuation and Earnings

This table compares Cryolife and Steris’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cryolife $180.38 million 3.17 $10.77 million $0.28 61.07
Steris $2.61 billion 2.78 $109.96 million $2.84 30.16

Steris has higher revenue and earnings than Cryolife. Steris is trading at a lower price-to-earnings ratio than Cryolife, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

72.6% of Cryolife shares are held by institutional investors. Comparatively, 89.5% of Steris shares are held by institutional investors. 6.0% of Cryolife shares are held by company insiders. Comparatively, 2.6% of Steris shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


This table compares Cryolife and Steris’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cryolife 5.28% 6.43% 4.33%
Steris 9.42% 11.57% 6.80%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cryolife and Steris, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cryolife 0 0 4 0 3.00
Steris 0 2 3 0 2.60

Cryolife presently has a consensus target price of $23.63, suggesting a potential upside of 38.16%. Steris has a consensus target price of $80.25, suggesting a potential downside of 6.30%. Given Cryolife’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Cryolife is more favorable than Steris.


Steris beats Cryolife on 9 of the 17 factors compared between the two stocks.

Cryolife Company Profile

CryoLife, Inc. (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc. valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix. PhotoFix is a pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde. The Preservation Services segment includes external services, such as preservation of cardiac and vascular tissues. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve and the CryoPatch SG pulmonary cardiac patch, both of which are processed using CryoLife’s SynerGraft technology.

Steris Company Profile

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others. Its Corporate and other segment includes the Defense and Industrial business unit.

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with's FREE daily email newsletter.